Erick Moy

Erick Moy joined Flagship Pioneering in 2023 as a Senior Scientist in the in vitro pharmacology and biology group for Pioneering Medicines. He is responsible for planning, developing and conducting in vitro studies for portfolio projects and exploratory biology programs.

As a cell biologist and immunologist, Erick brings a multidisciplinary background in biological research to his role. He joined Flagship from Pfizer’s Inflammation and Immunology research unit where he was involved in immuno-oncology, immunometabolism, cytokine signaling, and immune tolerance programs. He was a key contributor to the advancement of multiple programs to the clinic, including Pfizer’s Litfulo^TM (ritlecitinib) and Cibinqo^TM (abrocitinib).

Prior to joining Pfizer, Erick was a member of the biology research unit of Momenta Pharmaceuticals and contributed to the development of Glatopa, Momenta’s complex generic glatiramer acetate biosimilar.

A proud Wolverine, Erick earned his M.S. in Biomedical Engineering and B.S.E. in Materials Science and Engineering from the University of Michigan, Ann Arbor. He worked under the tutelage of Jon Rowley, founder of RoosterBio, Inc. and David J. Mooney, currently Professor of Bioengineering at Harvard University.